Hair Loss Claim Substantiation: TrichoScan, Hair Count & Tensile Strength Methods

Overview #

Hair loss claims are where brands get into trouble fast. Not because the actives don’t work — some of them genuinely do — but because the claim substantiation methodology is almost always an afterthought. We see this constantly: a brand selects an ingredient, builds a formula, then asks us six months later how to back up “reduces hair loss by 40%.” That’s the wrong order. The measurement method has to be chosen before the formula is locked, because different actives perform differently depending on which endpoint you’re measuring. TrichoScan, manual hair count, and tensile strength testing are not interchangeable. Each one tells you something different, and each one has a different failure mode at scale.

Established vs. Next-Generation Actives: What We’re Actually Working With #

The classic actives in this space — minoxidil (OTC drug in most markets, cosmetic in some), caffeine, saw palmetto extract, and biotin — have been around long enough that we know their stability profiles cold. Caffeine at 1.0–4.0% in a leave-on scalp serum is straightforward. Saw palmetto lipid extract needs to be kept below 40°C during processing or you get oxidative degradation that shows up as a rancid off-note by week 6 of accelerated stability. Biotin is water-soluble and stable, but honestly, the topical biotin story is weak. Most of the clinical evidence is for oral supplementation. We still formulate it in because brands want it on-pack, but we’re not convinced the topical mechanism is strong enough to anchor a primary claim.

The newer actives are more interesting and more complicated. Here’s how we compare the main candidates we’re currently working with across brand briefs:

A few things that table doesn’t capture. Redensyl is probably the most-cited next-gen active right now, and the supplier data is genuinely compelling — but we’ve had batches where the DHQG fraction degrades faster than the spec sheet suggests when the formula pH drifts above 6.5 during fill. We now require pH verification at fill point, not just at batch release. That’s a process control step we added after one client’s 12-week stability showed a 15% potency drop that wasn’t predicted by the accelerated data.

Capixyl is expensive. At 3% in a 30ml serum, the raw material cost alone is pushing $1.80–2.50 per unit before you add anything else. Most indie brands can’t absorb that at MOQ 3,000 units and still hit a viable retail margin. We almost always push back on this brief and suggest a Capixyl/Procapil blend at lower individual concentrations — the combined mechanism (peptide signaling + DHT pathway) is arguably more complete anyway.

For peptide-based actives and their formulation considerations, the pH window is the critical variable. Acetyl tetrapeptide-3 in Capixyl starts showing hydrolysis above pH 7.0 in our stability chambers. Keep it between pH 5.5–6.5 and you’re fine for 24 months. Go higher and you’re losing efficacy before the product reaches the consumer.

Claim Substantiation Methods: Choosing the Right Tool Before You Lock the Formula #

This is where most projects go sideways. The three primary methods — TrichoScan digital phototrichogram, manual hair count (standardized photography + counting), and tensile strength / hair pull force testing — measure fundamentally different things. Choosing the wrong one for your active’s mechanism of action means your clinical data won’t support your claim even if the product works.

TrichoScan is the gold standard for density and anagen/telogen ratio claims. It uses epiluminescence microscopy combined with image analysis software to count hairs per cm², measure shaft diameter, and calculate the anagen rate. The method is validated, reproducible, and accepted by EU regulatory bodies under EU Cosmetics Regulation 1223/2009 for substantiating “reduces hair loss” and “increases hair density” claims. The limitation: it requires a trained operator, a clinical site with the equipment, and a minimum of 60 subjects to get statistical power for a density endpoint. Budget €40,000–€80,000 for a properly powered TrichoScan study. Brands are often shocked by that number.

Manual hair count (standardized 60-second hair collection or comb test) is cheaper and more accessible, but it measures shedding, not density or growth. It’s the right method if your active works primarily through the telogen effluvium pathway — reducing excessive shedding rather than stimulating new growth. Caffeine and some DHT-blocking actives fit this profile. The problem is that “reduces hair shedding by X%” is a weaker consumer claim than “increases hair density.” We’ve had brand partners insist on the density claim but only budget for a shedding study. That mismatch creates a compliance problem.

Tensile strength testing measures the mechanical properties of the hair shaft — break force, elongation at break, and Young’s modulus. It’s relevant for claims about hair strength, breakage reduction, and fiber integrity. It’s not a growth claim. If you’re formulating a scalp serum with a hair-strengthening angle — keratin peptides, ceramides, hydrolyzed proteins — tensile testing is appropriate. For scalp health and hair growth formulation approaches, we typically recommend combining a shedding endpoint with a tensile endpoint when the formula contains both a growth active and a conditioning agent. Two endpoints, one study, more claim territory.

The clinical study we reference most often internally for Redensyl is the supplier-sponsored double-blind, randomized, placebo-controlled trial: n=26 subjects (male and female, androgenetic alopecia), 3-month treatment period, 3% Redensyl in a leave-on serum applied twice daily. TrichoScan endpoint. Result: 17% increase in hair density vs. baseline, compared to 7% in the placebo group. Statistically significant at p<0.05. The study is real and the design is solid. What it doesn’t tell you is how the formula was preserved, what the pH was, or whether the result holds at 6 months. We’ve seen supplier studies stop at 12 weeks for a reason.

The FDA Cosmetics Guidelines draw a hard line between cosmetic claims (“improves the appearance of fuller hair”) and drug claims (“stimulates hair regrowth”). In the US market, any claim that implies a physiological effect on the hair follicle — including “reactivates hair follicle stem cells,” which is a phrase we see in supplier marketing decks constantly — risks OTC drug classification. We flag this to every brand partner before the claim brief is written. The EU is somewhat more permissive on mechanism language, but the SCCS Scientific Opinion on specific actives like caffeine provides useful guidance on what’s substantiated vs. what’s marketing.

Where the Scale-Up Failures Actually Happen #

Lab scale is deceptive in this category. We’ve had formulas that looked perfect at 500g — stable, elegant texture, good sensory — fall apart at 150kg production for reasons that weren’t obvious.

One specific failure: a caffeine + Redensyl scalp serum, pH 5.8, preserved with phenoxyethanol/ethylhexylglycerin at 1.0%. Passed challenge testing at lab scale. At 200kg batch, gram-negative organisms appeared at week 8 of preservative challenge testing. The root cause was the larger batch requiring a longer hold time in the mixing vessel before fill, during which the temperature dropped through a range that temporarily reduced preservative efficacy. We added a secondary preservative booster (sodium benzoate at 0.3%) and moved to a hot-fill process for the aqueous phase. Problem solved, but it cost the client an extra four weeks and a reformulation fee.

Another one: a Procapil + biotin serum where the client requested a “clean” preservative system — no phenoxyethanol, no parabens. We used a gluconolactone/sodium benzoate system at pH 4.2. Worked at lab scale. At production scale, the pH crept up to 4.6 during batch due to the buffering capacity of the botanical extracts in the formula. At pH 4.6, the sodium benzoate system is significantly less effective. We had to reformulate the buffer system entirely. A lot of clean beauty brands underestimate how fragile low-pH preservative systems become at production scale. This is not a theoretical risk. We see it regularly.

Honestly, the tensile strength testing failures are less dramatic but more common. Brands request a hair strengthening claim, we run tensile testing on the lab batch, results look good. Then the production batch uses a slightly different molecular weight distribution of the hydrolyzed keratin (supplier lot variation), and the tensile improvement drops from 18% to 9%. Not enough to anchor the claim. We now require certificate of analysis with molecular weight distribution data from every hydrolyzed protein lot before it enters production.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a hair loss brief comes in, because the answers determine everything — the active selection, the claim methodology, the regulatory pathway, and the study budget.

If you’re targeting the EU market with a density claim, budget for TrichoScan and plan for a 3-month minimum study timeline before you can substantiate. If you’re going US DTC with a shedding claim, a well-designed 60-day comb test study is defensible and significantly cheaper. If you want both markets, you need a study design that satisfies both, which means working with a CRO that understands both regulatory frameworks from the start.

On active selection: for a first launch in this category, we typically recommend Procapil or Anagain as the primary active. Both have reasonable supplier clinical data, manageable cost, and stable formulation profiles. Redensyl is a stronger story but requires tighter process control. Capixyl is the premium option — reserve it for a hero SKU where the retail price supports the COGS.

For packaging, airless pump is strongly preferred for any formula containing peptide actives or light-sensitive components. Standard pump with a dip tube introduces oxygen with every actuation. Airless adds $0.40–0.80 per unit at MOQ 3,000, which is real money, but losing 20% peptide potency by month 3 is worse. We’ve stopped recommending open-pump packaging for Redensyl formulas entirely.

Stability protocol: we run 40°C/75% RH accelerated plus 25°C/60% RH real-time as standard, with potency testing at T0, T1, T3, T6. If you’re making a specific active concentration claim on-pack, you need the potency data. Don’t skip it.

Frequently Asked Questions #

Q: We want to claim “reduces hair loss by 40%” — what study do we need to back that up?

That specific number requires a controlled clinical study with a validated shedding endpoint — typically a standardized 60-second hair collection test or a TrichoScan anagen/telogen ratio measurement. You need a minimum of 40–60 subjects, a placebo or vehicle control arm, and a 12-week treatment period to generate data that’s defensible under EU claim substantiation guidelines. Budget €25,000–€50,000 for a properly designed study.

Q: Can we use the supplier’s clinical data for our claim, or do we need our own study?

You can use supplier data as supporting evidence, but it has to match your formula — same active, same concentration, same vehicle type. If your formula differs from the supplier’s test formula, the data is supporting, not primary. For a strong on-pack claim, we recommend at least a consumer perception study (n=30 minimum) on your actual formula, even if you’re leaning on supplier clinical data for the mechanism story.

Q: Is TrichoScan required, or can we use photography-based hair count?

TrichoScan is not legally required — it’s a methodology choice. Standardized macrophotography with manual or software-assisted hair counting is accepted, but it has lower reproducibility and requires a larger sample size to achieve the same statistical power. For a density claim, TrichoScan at n=60 is more defensible than photography-based counting at n=60. For a shedding claim, photography isn’t the right tool anyway.

Q: We’re launching in both the US and EU — do we need separate studies?

Not necessarily separate studies, but the study design has to satisfy both frameworks from the start. The EU requires claim substantiation under EU Cosmetics Regulation 1223/2009; the US requires that claims don’t cross into drug territory per FDA Cosmetics Guidelines. A well-designed study with a cosmetic-language endpoint — “appearance of fuller, denser hair” rather than “stimulates follicle activity” — can work in both markets. Get the claim language reviewed before the study protocol is written, not after.

Q: What’s the minimum concentration of Redensyl we can use and still make a claim?

The supplier’s clinical data is at 3.0%. We’ve seen brands try to reduce to 1.5% to cut COGS. At 1.5%, you’re outside the studied concentration range and the claim is not substantiated by the existing data. If you want to use a lower concentration, you need your own study at that concentration. Short answer: use 3.0% or don’t make the claim. The NMPA in China has similar expectations for substantiation alignment with use concentration — see NMPA Cosmetic Regulation for the current cosmetic claim filing requirements.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.